Clinical Trials
8 trialsNCT02953509 2025-05-29
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1/2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03422523 2022-08-22
ARGO
University Hospital Southampton NHS Foundation Trust
Phase 2 Terminated
NCT03488251 2022-08-16
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Molecular Templates, Inc.
Phase 2 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT02359162 2018-05-09
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Sun Yat-sen University
Phase 3 Terminated
NCT02533323 2018-05-09
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Sun Yat-sen University
Phase 2 Terminated
NCT00101205 2014-02-24
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated